**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Maria Ungericht, Department of Cardiology & Angiology, Medical University of Innsbruck, Innsbruck, Austria

**Main Body of the Abstract**
Background: The true prevalence of obstructive coronary artery disease (CAD) in cardiac amyloidosis (CA) is still underestimated. This study aimed to assess the prevalence, clinical relevance, and outcome of CAD in CA-patients.
Methods: We retrospectively analyzed the CAD prevalence in CA-patients in six Austrian amyloidosis centers. We also investigated differences in cardiac biomarkers, ECG and clinical characteristics in patients with and without CAD. Survival was further investigated in a single-center.
Results: 337 patients with CA (ATTR 72%, AL 28%) were included, with coronary angiography available in 204 (61%) patients. 96 of them (47%) were diagnosed with severe CAD. There was a stark difference in CAD prevalence between the ATTR and AL cohort (ATTR 51% vs. AL 35%, p=0.041). There were no significant differences in clinical symptoms (p=0.545), functional capacity (6-minute-walk-test, p=0.196), and ECG (pseudoinfarction pattern, p=0.404) between patients with and without CAD. In the ATTR-cohort, the presence of CAD was associated with higher NT-proBNP levels (p=0.019). In a single-center outcome analysis including 132 patients, no significant difference was observed in the mortality rate between patients with CAD (18% deaths) and those without CAD (25% deaths) (p=0.939).
Conclusion: CAD is highly prevalent in CA-patients with a significant difference between ATTR and AL. The higher prevalence in ATTR is possibly due to the older age in this group. The presence of a pseudoinfarction pattern (ECG) did not serve as a reliable indicator of CAD. The presence of CAD must be considered in CA-patients.



Prevalence and outcome of coronary artery disease in cardiac amyloidosis: A retrospective Austrian multicenter study PC44 (#356)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.